Introduction
MicroRNAs (miRNAs) are short non-coding RNAs that bind to the 3# untranslated region (UTR) of cognate messenger RNAs (mRNAs) through fully complementary or imperfect base-pairing repressing the translation or decreasing the stability of the bound mRNAs (1) . Accumulating evidence indicate that miRNAs are key regulatory molecules in various biological processes, including differentiation, self-renewal, immunity, proliferation and metabolism. The miRNAs in the human genome is estimated to regulate up to 30% of all the protein coding genes (2) . Currently, .9000 miRNAs have been identified in different species according to the miRBase release 13.0 (http://microrna .sanger.ac.uk/sequences/).
Cell invasion is a normal physiological process during embryonic and fetal development. In adult, invasive cell growth takes place in the bone marrow, where hemopoietic precursors migrate from their niches crossing blood vessels to reach the circulation (3) . Pathological invasion is often found in tumor metastasis, which is a major cause of cancer death (4) . Evidence is accumulating that miRNAs regulate cell invasion. In breast cancer, miR-21 promotes invasion and metastasis by suppressing the expression of tropomysin 1, maspin and programmed cell death 4 protein, whereas miR-373 and miR-520c enhance these processes through reducing CD44 expression. On the other hand, miR-205 suppresses breast cancer invasion, and miR-126 inhibits invasion in non-small-cell lung carcinoma cell lines (reviewed in ref. 5 ). In fact, miRNAs potentially regulate a number of genes that are involved in invasion like matrix metalloproteinase (MMP)-2, tissue inhibitor of metalloproteinase-2 and -3 (6) . miR-34a is highly expressed in normal tissues, like testis, lung, adrenal gland and spleen, though its physiological function is unknown (7) . Yet, it is one of the first and best-studied miRNAs related to carcinogenesis. miR-34a is commonly repressed in tumors like neuroblastoma, colon cancer and non-small-cell lung cancer cell lines (8) . The tumor suppressor protein p53 induces transcription of miR-34a and the expression of miR-34a correlates well with that of p53 in a number of cell lines, primary mouse embryonic fibroblasts and in irradiated mice (9) (10) (11) (12) . miR-34a is located on chromosome 1p36.23, which is a region associated with a variety of cancers. The antitumor functions of miR-34a can be p53-or p53-pathway dependent (10, 13) . miR-34a induces G 1 arrest (9, 14) , apoptosis and senescence (10) (11) (12) 14) . A number of target mRNAs of miR-34a have been suggested including Bcl-2 (11), cyclin E2 (CCNE2) (15) , E2F3 (16) , Mycn (17) , cyclin D1 (CCND1), c-Met (9) and Sirtuin 1 (13) .
Notch signaling is a highly conserved signaling pathway. Notch receptors are type I membrane-bound receptors. There are four Notch receptors (Notch 1-4) and 5 Notch ligands [Delta-like (DLL)-1, -3 and 4 and Jagged1 and 2 (Jag1/2)] in mammals. Notch receptors function as extracellular signal recipients at the cell surface and also act as transcription factors regulating gene expression inside the nucleus. Upon ligand binding, the Notch receptor protein is cleaved, releasing the intracellular domain of Notch (ICN) (18) , which is translocated into the nucleus and acts as a transcription factor controlling the expression of downstream genes involved in differentiation, cell fate specification, proliferation, apoptosis, adhesion and angiogenesis (19) . Abnormal Notch signaling is associated with tumorigenesis (20) (21) (22) and cell invasion (23) (24) (25) .
Although the anti-proliferation role of miR-34a is well known, its action on cell invasion is just begun to be explored. There is only one recent report demonstrating that miR-34a suppresses invasion via c-Met in HepG2 cells (26) . In this study, we demonstrate that miR-34a regulates the expression of Jagged1 and its receptor Notch1 and that forced expression of miR-34a causes a reduction of the invasion capacity of cervical cancer and trophoblast cell lines through inhibition of Jagged1 and Notch1 expression. Besides, the reduction of invasion capacity by miR-34a can be nullified by Notch ICN transfection. Finally, we found that the expression of urokinase plasminogen activator (uPA) was suppressed in miR-34a and Notch1 knockdown cells. Thus, miR-34a regulates the invasion capacity of cells by suppressing uPA mediated by Notch1 and Jagged1.
Materials and methods
Cell culture and reagents Human cervical cancer cell lines HeLa, SiHa, C4I, C33a and CaSki (American Type Culture Collection, Manassas, VA) were cultured in Dulbecco's modified Eagle's medium (Invitrogen, Carlsbad, CA). The trophoblast cell lines BeWo and JAR (American Type Culture Collection) were cultured in RPMI medium (Sigma, St Louis, MO). Both media were supplemented with 10% fetal bovine serum (Invitrogen), 50 U/ml of penicillin and 50 lg/ml of streptomycin (Invitrogen) . c-Secretase inhibitor DAPT (N-[N-(3,5-difluorophenacetyl)-lalanyl]-S-phenylglycine t-butyl ester) was purchased from Sigma.
Total RNA extraction and reverse transcription polymerase chain reactions Total RNA (large and small size RNAs) was extracted using the mirVana TM miRNA Isolation Kit (Ambion, Austin, TX) according to the manufacturer's protocol. The TaqManÒ MicroRNA reverse Transcription kit or the High capacity cDNA reverse transcription kit (Applied Biosystems, Foster City, CA) was used to synthesize the complementary DNA templates. miRNAs and mRNAs were quantified by the TaqManÒ MicroRNA Assays and the TaqManÒ Gene Expression Assays (Applied Biosystems), respectively. Real-time reverse transcription-polymerase chain reactions were performed in an Applied Biosystems 7500 Detection system (Applied Biosystems), the expression of miRNA was determined from the threshold cycle (C t ), and the relative expression levels were calculated by the 2 ÀDDC t method (27) . For miRNA, the C t values were normalized with reference to the expression of RNU6B. The same method was employed for mRNA quantification and the relative expression levels were normalized with the expression of 18S mRNA.
Luciferase assays and beta-galactosidase enzyme assay Oligonucleotides were synthesized according to the nucleotide sequence of potential miR-34a-binding regions identified by TargetScan 4.2 on Notch1 and Jagged1 (155-206 of Notch1 3# UTR and 1279-1330 of Jagged1 3# UTR, the sequences of the oligonucleotides were listed in supplementary Table 1 , available at Carcinogenesis Online). Digestion sites for HindIII and SpeI were added to the 5# and 3# end of the binding site in the 3# UTR of the predicted targets. The oligonucleotides were annealed and digested by HindIII and SpeI, respectively. The DNA fragments were then cloned downstream of the luciferase gene between the HindIII and SpeI sites in the pMIR-Reporter Expression Vector (Ambion). The reporter construct, the pSV-beta-galactosidase control vector (Promega, Madison, WI) and either the pre-miR-34a or the premiR-scramble control were transfected into HeLa cells. Pre-miR TM miRNA precursor molecule of miR-34a (pre-miR-34a) or pre-miR scramble (Ambion) into the cells. Pre-miR-34a is small chemically modified double-stranded RNA molecules designed to produce mature miR-34a within the transfected cells. The control precursor (pre-miR scramble) is a random sequence of nucleotides with size similar to the precursor molecule. It has been extensively validated in various human cell lines and tissues not to produce noticeable effects on known miRNA functions (Ambion). After 48 h, the cells were lysed and the luciferase activities in the lysate were measured by the Dual Luciferase Reporter Assay System (Promega), whereas the beta-galactosidase enzyme activities were measured by the beta-galactosidase enzyme assay (Promega). The latter was used to estimate the transfection efficiency.
Proliferation assays
The XTT colorimetric assays (Roche, Penzberg, Germany) were performed to estimate the cell proliferation rate according to the manufacturer's protocol. The cells were incubated for 3 h after adding the colorimetric reagents. Proliferation at different time points was assessed by measuring the absorbance at 450 nm using an ELISA plate reader (Tecan Group Ltd, Männedorf, Switzerland).
Forced expression and RNA interference (small interfering RNA) of Notch1 expression The expression of Notch1 was inhibited with the use of small interfering RNA (siRNA) gene silencer (Santa Cruz Biotechnology, Santa Cruz, CA). The downregulation of Notch1 was confirmed by western blotting using specific antibody. Forced expression of Notch1 ICN was achieved by transfecting the cells with a Notch ICN expression plasmid (pCDNA6-Notch ICN, a kind gift from Prof. Jon Aster, Brigham and Women's Hospital and Harvard Medical School, Boston, MA). Control cells were transfected with the empty construct (pCDNA6). The complementary DNA construct was co-transfected with either pre-miR-34a or pre-miR scramble into the cells.
Forced expression and knockdown of miR-34a
To examine the effect of miR-34a overexpression, pre-miR-34a or pre-miR scramble was transfected into the cells. miR-34a knockdown was performed by using the miRCURY LNA TM miRNA knockdown probes from Exiqon (Vedbaek, Denmark). The cells were seeded at a density of 3.5 Â 10 5 cells in six-well tissue culture plates 24 h before transfection with 50 nM of either pre-miR-34a or pre-miR scramble. The cells were then either subjected to XTT assay, protein/RNA extraction or invasion assays.
Invasion assay
The BD Matrigel Invasion Chamber (8 lm pore size; BD Biosciences, Franklin Lakes, NJ) was used to assess the invasion capacities of the cells. For DAPT treatment, the cells were either pre-treated with 10 lM of DAPT or dimethyl sulfoxide for 24 h before they were seeded into the upper compartment of the invasion chamber filled with fetal bovine serum-free culture medium, whereas the lower compartment was filled with normal culture medium supplemented with 10% fetal bovine serum as chemoattractant. For assessing the effect of miR-34a on cell invasion capacity, the transfected cells were seeded into the upper compartment of the invasion chamber containing medium supplemented with 0.5 lg of recombinant Jagged1 peptide or 0.5 lg of recombinant DLL1 (R&D systems, Minneapolis, MN), whereas the lower compartment was filled with normal culture medium as described above. After 24 h, the cells remained in the upper compartment were removed by cotton swabs, and those that had invaded through the matrix were stained by cell stain (Millipore, Billerica, MA). The stain in the cells was then dissolved in 10% acetic acid and the absorbance was measured by an ELISA plate reader. To confirm that the observable change was not due to differences in cell proliferation after treatment, a parallel experiment was conducted under the same conditions for the determination of the proliferation rate by XTT colorimetric assays as stated above.
Western blot analysis Cells were lysed in RIPA lysis buffer [phosphate-buffered saline with 1% Nonidet P-40 (Ameresco, Solon, OH), 0.5% sodium deoxycholate (Sigma), 0.1% sodium dodecyl sulfate (Sigma) and 2.5 ll/ml of Protease Inhibitor Cocktail (Calbiochem, Darmstadt, Germany) and phenylmethanesulphonyl fluoride at 4°C for 30 min. The protein concentrations were determined by the RC DC Protein Assay Kit (Bio-Rad, Hercules, CA) according to the manufacturer's instructions. The expression of Notch1, Jagged1 and b-actin were detected using specific anti-Notch1, anti-Jagged1 (Santa Cruz) and anti-b-actin (GE Healthcare, Waukesha, WI) antibodies, respectively.
Statistical analysis
Each experiment was repeated for at least three times independently. All the values were reported as means ± SDs. Differences between experimental and control groups were analyzed by Kruskal-Wallis test. P ,0.05 was considered as statistically significant.
Results miR-34a is expressed in cervical cancer and choriocarcinoma cell lines miR-34a was expressed in all the cell lines investigated. Its expression levels in HeLa and C33a were very similar ( Figure 1A ). While the expression of miR-34a in C4I and CaSki was about half of that in HeLa, the expression in SiHa was 2.5-fold higher. The choriocarcinoma cell lines BeWo and JAR also expressed miR-34a to a level that is very similar to most of the cervical cancer cell lines examined. PremiR-34a was transfected into the JAR, SiHa and HeLa cells. With the use of a miRNA quantitative-polymerase chain reaction assay that detected only the mature form of miRNA, we confirmed that the pre-miR-34a was processed to the mature form inside the transfected cells (supplementary Figure 1 is available at Carcinogenesis Online) and such transient transfection of miR-34a did not affect the proliferation ( Figure 1B ) and morphological appearance (data not shown) of the cells.
Notch1 and Jagged1 are functional targets of miR-34a
In silico miRNA targets identification tools PicTar (http://pictar.mdcberlin.de/) and TargetScan 4.2 (http://www.targetscan.org/vert_42/) identified Notch1 and Jagged1 as potential targets of miR-34a (supplementary Figure 2A and B are available at Carcinogenesis Online). Bioinformatics search also showed that the putative miR-34a-binding regions in the 3# UTR of Notch1 and Jagged1 mRNA were conserved among species. To confirm that Notch1 and Jagged1 were putative targets for miR-34a, luciferase reporter construct carrying the 3# UTR miR-34a potential-binding site or miR-34a mutant-binding sites of Notch1 and Jagged1 were constructed and co-transfected with either pre-miR-34a or pre-miRscramble and b-gal expression vector into the HeLa cells. The luciferase signal obtained was normalized with the respective b-gal activity. Compared with the control, transfection with pre-miR-34a reduced the luciferase activities significantly (Figure 2A) . However, the pre-miR scramble or pre-miR-34a did not affect the luciferase activity in the mutant construct and their luciferase activities did not have any significant differences when compared with the control.
Western blot analysis using specific antibody against Notch1 showed that the expression level of Notch1 protein was decreased by 24 and 31% in the pre-miR-34a-transfected HeLa and JAR cells, respectively ( Figure 2B) . Similarly, the expression of Jagged1 in the HeLa and JAR cells was decreased by 20 and 25%, respectively upon pre-miR-34a transfection ( Figure 2C ). The expression of the Notch target gene Hairy Enhancer of Split-1 (Hes-1) (28) was likewise affected; Hes-1 expression was reduced in the pre-miR-34a-transfected cells ( Figure 2D ). Besides, we have knockdown miR-34a in SiHa cells that has the highest endogenous miR-34a expression. We found that the expression of Notch1, Jagged1 and Hes-1 were increased (supplementary Figure 3 is available at Carcinogenesis Online). Thus, alteration of miR-34a expression not only affected the expression of Notch1 and Jagged1 but also influenced Notch signaling.
MiR-34a decreases the invasion capacity of cervical cancer and choriocarcinoma cells HeLa and JAR cells transfected with either pre-miR-34a or pre-miR scramble were seeded into the invasion chambers in the presence of recombinant Jagged1 and their invasive potential was determined. The results demonstrated that forced expression of miR-34a significantly suppressed invasion in both cell types ( Figure 3A and B) ; the invasiveness of HeLa and JAR cells was reduced by 65.0 and 61.9%, respectively. We had also included another Notch ligand DLL1 as control in the experiment. Currently, there is no evidence that DLL1 is a target of miR-34a. We found that the invasion capacity was also decreased (supplementary Figure 4 is available at Carcinogenesis Online), consistent with the fact that DLL1 is a ligand of the Notch1 receptor and the Notch1 receptor is downregulated in the transfected cells. To exclude the possibility that the observed change in invasiveness was due to decrease in proliferation of the treated cells, the proliferation rates of the cells in the presence of the same concentration of recombinant ligands were determined by XTT assays. There was no significant difference in the proliferation rate between the pre-miR-34a and the pre-miR scramble-transfected cells ( Figure 3C ).
Proteosome inhibitor treatment decreases the invasive capacity
We hypothesized that Notch1/Jagged1 mediated the suppressive activity of miR-34a on cell invasion. To test the hypothesis, Notch signaling in HeLa and JAR cells was suppressed with the use of c-secretase inhibitor DAPT, which was widely used to inhibit the cleavage of the Notch receptor. The treatment significantly reduced the invasiveness without affecting the proliferation (supplementary Figure 5 is available at Carcinogenesis online) of these cells.
Knockdown of Notch1 decreases cell invasion
To provide further evidence that Notch affecting the invasion capacity, RNA interference probe specific for the inhibition of Notch1 expression was transfected into the cells and the invasion capacity were assayed. On average, $70-90% of Notch1 expression was knockdown ( Figure 4A ). Upon Jagged1 stimulation, the invasive capacity of the Notch1-suppressed cells was decreased significantly (Figure 4B and C) and the reduction was not due to change in the proliferation rate ( Figure 4D ).
Notch activation nullifying the effect of pre-miR-34a transfection
Transfection of Notch ICN with pre-miR scramble increased the invasion capacity of both HeLa and JAR cells. Forced expression of Notch ICN partially nullified the effect of pre-miR-34a in reducing invasion capacity in both cell types ( Figure 5A and B) . However, transfection of the empty expression vector did not have such effect and the invasion capacities were significantly different from the control (pcDNA6 and pre-miR scramble). Forced expression of Notch ICN or empty expression vector with the miRNA precursors did not have significant effect on cell proliferation ( Figure 5C ).
Forced expression of miR-34a suppresses uPA expression By using qPCR assay, we found that expression of uPA was decreased upon transfection of pre-miR-34a or siRNA-Notch1 ( Figure 6 ). However, uPA expression was increased when the cells were transfected with Notch ICN expression plasmid. Thus, it is highly possible that miR-34a regulates cell invasion by regulating uPA expression through Notch signaling.
Discussion miR-34a is mapped to chromosome 1p36.23. Genomic deletion or loss of heterozygosity of this chromosomal region has been reported in many types of tumors such as cervical cancer (29), breast cancer (30), neuroblastoma and lung cancer (31) . This report demonstrates for the first time conclusively that both Notch1 receptor and its ligand Jagged1 are the targets of miR-34a. Induction of expression of miR34a by transfection of pre-miR-34a suppresses the expression of these proteins in the transfected cells. Although one previous study suggested that Notch1 is a target of miR-34a, definitive evidence of such relationship was lacking (32) . In the present study, luciferase reporter The proliferation rate of the pre-miR-34a and pre-miR scramble-transfected cell lines as determined by the XTT proliferation assay. Each data point represented data from at least three independent measurements (±SD). There was no statistical difference between control and treatment at the same time point.
miR-34a suppresses invasion through notch downregulation assay provides supportive evidence that miR-34a binds to the potential 3# UTR-binding sites of these proteins, an initial event for miRNAs to elicit their biological actions. In addition, we found that the expression of Hes-1, a downstream molecule in Notch signaling was also affected through miR-34a induction. These observations indicate that miR-34a affects the Notch signaling pathway.
In the present study, all the tested cell lines express various levels of miR-34a and transient forced expression of which did not affect cell proliferation. However, miR-34a induces apoptosis, G 1 arrest and senescence in tumor cells (10) (11) (12) 14) . The discrepancy could be due to cell type-specific response to miR-34a. The action of miR-34a on cell cycle in colon cancer cells is p53 dependent; overexpression of miR-34a in colon cancer cells lacking p53 had neither effects on cell proliferation nor apoptosis (10, 13) . The cervical cancer cell lines used in this study have p53 that is either mutated or inactivated by the E6 oncoprotein of human papillomavirus. Infection with human papillomavirus has a causal link with cervical cancer (33) ; genomic integration of the viral DNA occurs in .99% of the cervical cancer specimens (34) . Upon infection, the viral E6 onocoprotein suppresses the functions of p53 (35) (36) (37) and the expression of miR-34a (38) . On the other hand, p53 is expressed in human placenta and trophoblast cell lines (39) and mutation of p53 is rare in trophoblastic neoplasia (39) (40) (41) . p53 is a transactivator of miR-34a (12) . Unlike many types of cancer, overexpression of p53 in complete mole and choriocarcinoma is associated with more aggressive behavior and not with cell cycle arrest or apoptosis (42) , suggesting that either the p53 downstream pathway is defective or mechanisms overriding the actions of p53 exist in these cells. One possibility is that the overexpression of Mdm2 in complete mole and choriocarcinoma (42) may inactivate p53 by forming p53-Mdm2 complex (43) .
The increase in miR-34a expression is associated with decrease in Notch signaling and invasive potential of HeLa and JAR cells. The relative expression levels of miR-34a seem to be in line with the reported invasiveness of the choriocarcinoma cells. The JAR cells have higher expression of miR-34a than the BeWo cells. The invasive capacity of the former is lower than that of the latter in invading re-epithelialized endometrial fragments and stromal tissues (44) . However, the expression levels of miR-34a in cervical cancer cells are not related to their invasive potential; the SiHa cells show the highest expression of miR-34a but are more invasive than the HeLa cells (45, 46) . This observation suggests that other factors in addition to miRNA are involved in controlling the invasive potential in cervical cancer cells.
Cell invasion occurs as a normal event in a number of physiological processes. During pregnancy, the cytotrophoblast differentiates into the syncytiotrophoblast and the extravillous cytotrophoblast. The latter invades the decidua. Insufficient invasion of the uterine wall cause preeclampsia and fetal intrauterine growth retardation. Notch1 and its ligands are expressed in the trophoblast and the cytotrophoblast (47). 
miR-34a suppresses invasion through notch downregulation
Here, we have demonstrated that miR-34a decreases the cell invasion through modulation of Notch1 expression. The result supports the clinical observation of a weaker Notch1 and Jagged1 expression in cytotrophoblast, syncytiotrophoblast and stroma of preeclamptic placentae than that of normal placentae (48) , consistent with the association of defective Notch signaling with trophoblast invasion in preeclamptic placentae. Whether the invasion capacity is regulated by miR-34a during trophoblast differentiation is unknown but our unpublished results indicate that the levels of miR-34a associates with Notch1 expression during syncytiotrophoblast differentiation.
Uncontrolled invasion leads to pathological conditions such as metastasis. Metastasis causes up to 90% of human cancer deaths (4) and tumor invasion represents the earliest sign of metastasis. Cervical cancer is often detected at late stages of metastasis in developing countries. Therefore, defining the mechanisms controlling metastasis is essential to improve cancer survival. Notch1 and Jagged1 are expressed in cervical cancer and their expression in invasive human cervical cancer is higher than that in high-grade precursor lesions (49, 50) . It has been suggested that activation of Notch signaling is associated with the progression of cervical neoplasia (51) . Recently, it was found that miR-34a acts as an independent miRNA prognostic marker of relapse in non-small-cell lung cancer (52) , whereas another group demonstrated that activation of Notch correlates with poor clinical outcome (53) . The association and prognostic value of Notch and miR-34a in cancer remains to be investigated.
In this study, Notch signaling mediates the suppressive activity of miR-34a on the invasiveness of HeLa and JAR cells; transfection of Notch ICN expression plasmid nullifies the effect of miR-34a on suppression of cell invasion. However, the effect of miR-34a in suppressing invasion capacity is stronger than its effect in suppressing Notch1 and Jagged1 expression. This indicated that there are additional miR-34a targets controlling cell invasion. In fact, it has been suggested that a single miRNA species potentially regulates many target genes and miRNA has the tendency to regulate a family of genes (54) . A recent study also demonstrated that miR-34a inhibited the invasion of human hepatocellular carcinoma cell line HepG2 through downregulation of the expression of tyrosine kinase receptor c-Met (26) . HeLa-S3 cells (55) express c-Met, and overexpression of c-Met correlates with the progression, recurrence and survival of invasive cervical carcinomas (56, 57) . In addition, Notch2 receptor is also expressed in cervical cancer cells (58) , suggesting functional redundancy of the Notch signaling pathway. Addition miR-34a targets genes controlling cell invasion awaited for further investigation.
Notch and Met signaling are probably to affect cell invasion via their action on the production of matrix degrading enzymes. uPA and its inhibitor type-1 (plasminogen activator inhibitor-1) are present in invasive cervical cancer tissue (59) . Cervical cancer cells, SiHa, C-33A, C-4II, CaSki and HeLa express MMP-2 and tissue inhibitor of metalloproteinase-2 (45) . On the other hand, the expression of these enzymes is known to be regulated by Notch or Met signaling in cancer cells. For instance, downregulation of Notch1 decreases MMP-9 in pancreatic cancer cells (23) and prostate cancer cells (25) and reduces uPA and uPA receptor in prostate cancer cells (25) . Similarly, suppression of c-Met reduces MMP2 and MMP9 in ovarian cancer cells (60) . Activation of Met signaling by hepatocyte growth factor treatment increases the expression of MMPs and uPA in cancer cells (61) . Here, we only detected a change of uPA level but not that of MMPs in pre-miR-34a transfected, Notch1 knockdown or Notch ICN-transfected cells (data not shown), suggesting that the control of invasion by Notch signaling is cell-type specific.
In summary, our results show that miR-34a regulates Notch signaling in cervical and choriocarcinoma cell lines. Forced expression of miR-34a inhibited not only Notch1 and Jagged1 expression but also Notch signaling and reduced cell invasion. In view of the present data and the reported actions of miR-34a in various cancer cells, we propose that miR-34a is a useful target molecule for developing new therapy against cancer. Fig. 6 . uPA expression was affected by pre-miR-34a and Notch ICN transfection. HeLa and JAR cells were transfected with either pre-miR-34a, siRNA of Notch1, Notch ICN expression vector or their own controls (pre-miR scramble, siRNA-control or pcDNA6 vector). The mRNA expression of uPA was quantified. The uPA expressions of the controls were set as 1 while the expression of the treatment groups were represented as fold over control.
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